Floatz logo

ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166

Breast Cancer

Fudan Universityantibody_drug_conjugatePhase 2Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
59/ 100

Competitive context

890 Active assets in the Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
ERIBULIN MONOMETHANESULFONATE
Henan Cancer Hospital
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB

View all 50 →

Same molecule, other indications

ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166 is also rated in:

HER2 positive breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →
HER2 Gene MutationDormant
CCC
Indicative ·
52 / 100
View asset →
tumor of salivary glandDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →